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Abstract
Background: Protein used in medicine, e.g. interferon, are immunogenic and quickly broken down
by the body. Pegylation is a recognized way of preserving their integrity and reducing immune
reactions, and works well with enzymes used to degrade amino acids, a recent focus of attention
in controlling cancer growth. Of the two arginine-degrading enzymes being explored clinically,
arginine deiminase is a decidedly foreign mycoplasm-derived enzyme, whereas human arginase 1 is
a native liver enzyme. Both have been pegylated, the former with adjuncts of 20 kD, the latter with
5 kD PEG. Pegylation is done by several different methods, not all of which are satisfactory or
desirable.
Methods: The preparation of novel polyethylene glycol (PEG) derivatives for modifying proteins
is described, but directed specifically at pegylation of recombinant human arginase 1 (rhArg1).
rhArg1 expressed in Escherichia coli was purified and coupled in various ways with 5 different PEG
molecules to compare their protective properties and the residual enzyme activity, using
hepatocellular cell lines both in vitro and in vivo.
Results: Methoxypolyethylene glycol-succinimidyl propionate (mPEG-SPA 5,000) coupled with
very high affinity under mild conditions. The resulting pegylated enzyme (rhArg1-peg5,000 mw) had
up to 6 PEG chains of 5K length which not only protected it from degradation and any residual
immunogenicity, but most importantly let it retain >90% of its native catalytic activity. It remained
efficacious in depleting arginine in rats after a single ip injection of 1,500 U of the conjugate as the
native enzyme, plasma arginine falling to >0.05 μM from ~170 μM within 20 min and lasting 6 days.
The conjugate had almost the same efficacy as unpegylated rhArg1 on 2 cultured human liver cancer
(HCC) cell lines. It was considerably more effective than 4 other pegylated conjugates prepared.
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Cancer Cell International 2009, 9:9 http://www.cancerci.com/content/9/1/9Conclusion: Valuable data on the optimization of the pegylation procedure and choice of ligand
that best stabilizes the enzyme arginase 1 are presented, a protocol that should equally fit many
other enzymes and proteins. It is a long lasting arginine-depleting enzyme in vivo which will greatly
improve its use in anti-cancer therapy.
Background
Arginine degrading enzymes have been used to treat can-
cer for some time [1,2]. We have recently published find-
ings with pegylated arginase both in vitro and in vivo [3,4];
a brief overview can be found in Cheng and Wheatley,
2007 [5] that show how effective pegylation can be in pro-
tecting even a native human enzyme from rapid elimina-
tion by one means and another from the bloodstream.
Hepatocellular carcinoma (HCC) is a prime example of a
tumour that should be amenable to treatment with this
enzyme, since they have previously been considered aux-
otrophic for arginine because they do not express
argininosuccinate synthetase (ASS; e.g. [6]). While the
arginine-depleting enzyme arginine deiminase (ADI) has
been used to treat ASS-deficient tumors [7], arginase can
also be effective in treating ASS-positive tumors because it
eliminates the constant recycling of citrulline in a manner
that cannot be emulated by the former enzyme [4]. The
latter report also recognised that another enzyme defi-
ciency was key in many HCC cases, viz. ornithine transcar-
bamylase (OTC), enhancing the possibility of a good
therapeutic response to arginase administration. This may
open up exciting possibilities for the effective treatment of
not only HCC, but probably a range of other tumours
where OTC levels are also under investigation.
There is currently a groundswell in the exploration of
arginine dependency of tumours of diverse types. What-
ever the enzyme preference for use in clinical work (and
one can also include, for example L-asparaginase [8] and
L-methioninase [9]), it is of paramount importance that it
is both safe and highly efficacious. Sometimes it is impos-
sible to achieve this without compromising activity, and
therefore if this can be avoided, improved preparations
may well be obtained. Arginase 1 is a natural liver enzyme,
but arginine deiminase is an enzyme expressed by myco-
plasm that can be purified from the culture medium, or
expressed as a recombinant form by transfection of E. coli
with the ADI gene, as for arginase 1. Irrespective of which
enzyme is chosen for use in cancer therapy, it would be of
considerable value to standardise a procedure that pro-
duces the optimal pegylation for the protection of the
enzyme against its rapid destruction in vivo while retain-
ing maximal activity against its substrate, arginine in this
case. It is also desirable that pegylation does not itself
have any associated toxicity producing undesirable side
effects. These are crucial matters that need to be investi-
gated and resolved to general satisfaction before many
more clinical studies are undertaken. We present data that
establishes for arginase 1 a mode of pegylation that meets
the required criteria, and which can be equally applicable
to many other suitable proteins (i.e. with free ε amino
groups).
Arginase is a urea cycle enzyme that catalyzes the hydrol-
ysis of L-arginine to L-ornithine and urea in a divalent cat-
ion-dependent (Mn2+) reaction [10]. Recombinant
human arginase I (rhArg1) has been successfully cloned
and expressed in Bacillus subtilis [11] and E. coli [12]. How-
ever, the unacceptably short circulatory half-life of native
arginase in the human body (t1/2 <30 min) makes it diffi-
cult to maintain a therapeutically effective (low) blood
arginine concentration in patients without frequent
administration of large doses that are – from an economic
viewpoint – difficult to sustain with the present availabil-
ity of the enzyme. The attachment of polymers to pro-
teins, e.g. polyethylene glycol (PEG), is an established
technique to enhance the therapeutic and biotechnologi-
cal potential of numerous proteins [13-16]. Examples of
protected proteins include: mPEG-IL-2 [17], mPEG-IFN-α
[18], pegylated recombinant interferon alpha-2b, recom-
binant methioninase [9], pegylated arginine deiminase
(ADI, another arginine-depleting enzyme; [7]), and
pegylated bovine liver arginase [19,20]. In the last exam-
ple, pegylated bovine liver arginase retained only ~65% of
its original enzymatic activity, only ~53% of the free
amino (mainly lysine) groups were conjugated with PEG
molecules, and its circulatory life was <12 h [19].
Improved techniques of pegylating arginase not only
enhance the half-life of arginase in vivo, but can quite pro-
foundly reduce the immunogenicity of the protein, pro-
tecting it from degradation by directly masking surface
antigens and sterically hindering interactions with anti-
bodies [13]. While this is mandatory with foreign
enzymes such as ADI [21], it is far less relevant where the
native human enzyme is used. rhArg1 may, however,
show some immunogenicity because of its expression in
the 6×His-tagged form in bacteria, and also because its
isolation and purification procedures do not ensure 100%
recovery of its native form [11]. However, its increased
size after pegylation reduces renal clearance, which also
helps prolong its circulatory half-life [16].
Five different pegylated forms of arginase 1 have been
examined (Fig. 1). We briefly report on their pharmacody-Page 2 of 13
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parameters, which show the relative absence of side
effects. In all, the following aspects have been taken into
account: (1) determination of the most appropriate type
of PEG molecule to use; (2) optimization of the condi-
tions for the pegylation reaction, (3) the effects of pegyla-
tion on enzyme activity, (4) the effectiveness of the
pegylated enzyme to deplete arginine in vivo (in rats), and
(5) the sensitivity of two human hepatocellular carci-
noma (HCC) cell lines in vitro to these pegylated mole-
cules. We found that conjugation of rhArg1 with mPEG-
SPA 5,000 proved most effective on all these accounts,
having already dismissed PEG 20,000 used by workers
favouring ADI as the catabolic enzyme of choice [5,22].
Results
Pegylation of rhArg1
rhArg1 was expressed in B. subtilis as a N-terminal 6×His-
tagged protein [4,11]. The enzyme was purified by nickel
affinity column chromatography, and ~100 mg of the
native rhArg1 (>95% purity) was routinely obtained per
liter of culture. Its MW was ~35 kDa when analyzed by
SDS-PAGE (lane 2 in Fig. 2).
mPEG-ALD, mPEG-NHS, mPEG-SPA and mPEG-CN are
all lysine-active PEGs. The most frequently used deriva-
tives for lysine attachment are the N-hydroxylsuccinimide
(NHS) active esters, such as PEG succinimidyl succinate
(mPEG-SS) and succinimidyl propionate (mPEG-SPA).
Reaction between the epsilon amino group of lysine(s) or
the N-terminal amine and the NHS ester produces a phys-
iological stable amide linkage(s). Increasing pH increases
the rate of reaction and lowering pH reduces rate of reac-
tion. These highly "active esters" can couple at physiolog-
ical pH, and low temperature can be used if a labile
protein is being conjugated. In this case, a long reaction
time is useful. Analysis of several reactions with varying
ratios of protein:PEG and at different pHs quickly provide
information to help decide the conditions giving the
required level of pegylation. Aldehydic preparations, such
as mPEG-ALD, are much less reactive than NHS esters. On
the other hand, coupling of sulfhydryl-selective PEG such
as mPEG-MAL 5,000 and thiol groups is one of the most
useful reactions for bioconjugate preparations. This reac-
tion is highly specific and takes place under mild condi-
tions in the presence of other functional groups. mPEG-
MAL has been used as a reactive polymer for preparing
well-defined bioactive PEG-protein conjugates. The sulf-
hydryl-selective chemistry of mPEG-MAL 5,000 is in
Phase II clinical trials.
rhArg1 was formulated (pegylated) with PEG molecules
of various linkers (see also Fig. 1). The relative enzyme
activities of the various types of pegylated rhArg1 are
Chemical structures (molecular formula) of the 5 PEG deriv-atives usedFigure 1
Chemical structures (molecular formula) of the 5 
PEG derivatives used. (A) mPEG-ALD (methoxypolyethyl-
ene glycol-propionaldehyde); (B) mPEG-MAL (methoxypoly-
ethylene glycol-maleimide); (C) mPEG-NHS (methoxypoly-
ethylene glycol-N-hydroxy-succinimide); (D) mPEG-SPA 
(methoxypolyethylene glycol-succinimidyl propionate). (E) 
mPEG-CN (methoxypolyethylene glycol-cyanuric chloride). 
MW = 5,000 in all cases.
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dramatic decrease in the enzyme's specific activity, a drop
of ~70% relative to the native rhArg1, whereas all other
pegylated forms only decreased activity by 10–15%.
mPEG-SPA (MW = 5,000) was selected as the most suita-
ble candidate for the pegylation of rhArg1, because the
resulting modified enzyme, designated rhArg1-peg5,000
mw, retained >90% of the native rhArg1 enzymatic activity
(Table 1). In addition, mPEG-SPA does not have an ester
linkage in the backbone (Fig. 1), and therefore generates
stable linkages, with nearly ideal reactivity for protein
modification. mPEG-SPA is being used in Pfizer's SOMA-
VERT (Pegvisomant for injection) for the treatment of
acromegaly (over-expression of human growth hormone)
in patients who responded poorly to surgery and/or radi-
ation therapy [23].
To optimise the reaction time and the amount of mPEG-
SPA required for the complete pegylation of rhArg1, the
native enzyme was incubated with 1: 20 and 1: 50 mPEG-
Table 1: rhArg1 was reacted with five different PEGs, varying in linker chemistry. 
Type of PEG used for pegylation rhArg1: PEG ratio (mol/mol) for pegylation Relative arginase activity (%)
Native rhArg1 --- 100
mPEG-SPA 1:20 94
1:50 93
mPEG-NHS 1:20 86
1:50 83
mPEG-MAL 1:20 85
1:50 84
mPEG-ALD 1:20 88
1:50 88
mPEG-CN 1:20 34
1:50 30
Different forms of pegylated rhArg1 were prepared, purified and analyzed for their specific activities. Relative arginase activity indicates the specific 
activity of pegylated rhArg1 with respect to native rhArg1.
SDS-PAGE (15% gel) analysis of native and mPEG-SPA pegylated rhArg11Figure 2
SDS-PAGE (15% gel) analysis of native and mPEG-SPA pegylated rhArg11. Time-course of the pegylation reaction 
with 1:20 and 1:50 (mol/mol) of rhArg11:mPEG-SPA. Lane 1, low-range protein marker; Lane 2, native rhArg1; Lane 3, 1:20 
mole ratio (0.5 h); Lane 4, 1:20 mole ratio (1 h); Lane 5, 1:20 mole ratio (2 h); Lane 6, 1:20 mole ratio (3 h); Lane 7, 1:20 mole 
ratio (20 h); Lane 8, 1:50 mole ratio (0.5 h); Lane 9, 1:50 mole ratio (1 h); Lane 10, 1:50 mole ratio (2 h); Lane 11, 1:50 mole 
ratio (3 h); Lane 12, 1:50 mole ratio (20 h).
1   2     3   4    5    6    7       8   9    10   11  12  
31 kDa
22 kDa
14 kDa
66 kDa
45 kDa
97 kDa
Pegylated 
rhArg 
Native rhArg Page 4 of 13
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PEG molar ratio of 1: 50 was sufficient to ensure undetec-
table levels of native rhArg1 after 20 h of reaction. How-
ever, after 3 h of reaction, the amount of unmodified
rhArg1 was already close to undetectable, i.e. a further 17
h did not significantly increase the degree of pegylation
(Fig. 2). From these results the optimum rhArg1: PEG
ratio and reaction duration were found to be 1: 50 and 3
h, respectively. Under these mild conditions, the other
PEGs tested (mPEG-ALD, mPEG-MAL, mPEG-NHS and
mPEG-CN) gave only partial pegylation reaction products
and different amounts of native rhArg1 were still detected
(data not shown).
The pegylation reaction products generated by using
mPEG-SPA were analyzed by SDS-PAGE (Fig. 2), which
indicates that the MW of rhArg1 was increased after conju-
gation with mPEG-SPA. MALDI-TOF mass spectra of native
rhArg1 and PEG-conjugated rhArg1 are shown in Fig. 3.
Based on amino acid sequence, the calculated MW of native
rhArg1 is 35,558, consistent with the measured MW of
35,511 (Fig. 3A). The spectrum of pegylated rhArg1 has 6
peaks, labeled 1–6 in Fig. 3B, with m/z values of 41,008,
46,542, 52,112, 57,642, 63,126 and 68,598, respectively.
The number shown at the bottom of each peak in Fig. 3B
corresponds to the number of PEG conjugated to rhArg1.
The MW difference between adjacent peaks in the spectrum
is ~5,000, consistent with the average MW of the PEG used
for the pegylation of rhArg1. Polydispersity is a ratio that
represents the broadness of a molecular weight distribu-
tion. If the polydispersity is equal to 1, the polymer is said
to be monodispersed; typically, however, polymers are not
truly monodispersed. Therefore, we conclude that rhArg1-
peg5,000 mw has 1–6 molecules of PEG attached to the free
amino groups of Lys residues in arginase 1.
A pegylated protein is typically a mixture of varying num-
bers of PEGs of different molecular weights attached to
several amino acids. Each starting PEG sample used to
prepare a particular reagent contains a range of PEGs of
varying molecular weight (typical polydispersity values
are <1.05), hence proteins containing the same number of
PEGs will have a range of molecular weights. These PEGs
will be distributed on different amino acids.
Enzyme kinetic analysis
The Km value of native rhArg1 for the substrate arginine
was 1.9 ± 0.7 mM, which is similar to the Km values of
native human liver arginase (2.6 mM, [24]) and human
erythrocyte arginase (1.6 mM, [20]) for arginine. Intrigu-
ingly, the Km of pegylated rhArg1 (rhArg1-peg5,000 mw) was
found to be ~2.9 mM, indicating that the attached PEG
molecules on the surface of the enzyme did not dramati-
cally reduce the affinity for the substrate. These results are
at variance with those reported for pegylated bovine liver
arginase [19,25].
Arginase converts arginine to ornithine and urea. Despite
its strong in vitro anti-cancer properties, the bovine liver
arginase has never been seriously considered as a poten-
tial drug for the treatment of human cancers for several
reasons, including its much lower affinity for arginine
(Km, 6 mM for the native enzyme; Km, 12 mM for the
pegylated enzyme) at physiologic pH [25], a pH optimum
of 9.6, and a short circulatory half-life (a few minutes).
These have been considered serious shortcomings since
the 1980s, with the report from Savoca et al. [19] showing
no antitumor activity of bovine liver arginase in mice
bearing the Taper liver cancer. Other investigators have
also given negative reports on the bovine arginase [6]. It
appears that the bovine enzyme has quite different bio-
chemical properties compared with human liver arginase.
CD spectroscopic analysis
The changes in the secondary structures of rhArg1-peg5,000
mw compared to native rhArg1 were examined by CD spec-
troscopy in the far-UV region of the spectra covering the
wavelength range 190–250 nm (CD spectra shown in Fig.
4). The spectra of 2 enzymes both exhibited a negative
band (magnetic dipole) that is at ~200–240 nm and a
positive band (electric dipole) at ~195 nm.
A summary of the CD experimental data with regard to
the secondary structural compositions of rhArg1 and
rhArg1-peg5,000 mw (Table 2) strongly suggests that the
pegylated rhArg1 has no significant difference in second-
ary structure from the native rhArg1 since the percentage
composition of each class of structure only varied by a
maximum of 4% between the native and pegylated argin-
ases, consistent with the results showing that their enzyme
activities were similar (Table 1). Nor does pegylation
seem to prevent the access of arginine to the active site,
which is not unexpected given the small size of the sub-
strate.
Pharmacodynamic studies
The in vivo studies involved the ip injection of rhArg1 or
rhArg1-peg5,000 mw into rats, whose plasma arginine levels
were measured. The results (Fig. 5B) show that complete
arginine depletion was achieved with 1,500 U of
pegylated rhArg1 per rat (6 U/g of rat) for 6 days. In com-
parison, the highest dose of native rhArg1 (7,500 U/rat)
only reduced circulating arginine to ~20 μM within 3 h of
injection, with arginine levels returning to normal ~2 days
post-injection (Fig. 5A).
Ensor et al. [7] found that the circulation half-life of ADI
(a few hours) was prolonged by pegylation. The pegylated
ADI had a circulation half-life of 2–3 days. Although the
native ADI enzyme and the pegylated ADI were similar in
their ability to inhibit the growth of melanoma and HCCs
in vitro, only the pegylated ADI was effective in inhibiting
growth of these tumors in vivo. To achieve efficacy in vivo,Page 5 of 13
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MALDI-TOF-MS results of native and pegylated rhArg11Figure 3
MALDI-TOF-MS results of native and pegylated rhArg11. (A) MW of the native rhArg11 is ~35.5 kDa. (B) Numbers 
1–6 under the peaks correspond to the number of PEG conjugated; the numbers on the peaks indicate the mass-to-charge (m/
z) ratio values.
 (A) 
(B)
654321
Cancer Cell International 2009, 9:9 http://www.cancerci.com/content/9/1/9serum arginine levels must be maintained at low levels for
a sufficient time, and certainly at least 3 days.
Hematological and biochemical changes during arginine 
depletion
Most of the hematological, biochemical, and clinical
parameters were not significantly different between the
control and test groups. The relative organ weights are
summarized in Table 3, with only the brain showing for
some unknown reason a statistically significant change
between the control and treated groups.
In vitro anti-tumor activity
To compare the anti-tumor efficacies of rhArg1 and
rhArg1-peg5,000 mw, we applied the enzymes at a range of
concentrations in the culture medium of human HCC cell
lines (HepG2 and Hep3B). IC50 values (i.e. concentrations
achieving a 50% inhibition of cell growth) of rhArg1-
peg5,000 mw were determined at 0.2 and 0.1 U/ml in HepG2
and Hep3B cells, respectively, which is close to the results
with native rhArg1 (Table 4). The results demonstrated
that pegylated rhArg1 still has high anti-tumor efficacy
comparable to the native enzyme.
Discussion
Pegylation greatly improves the stability and solubility,
prolongs the circulation half-life, and lowers the immu-
nogenicity of proteins. However, enzyme activity is com-
monly affected by the process. For example, only a trace
biological activity remained in granulocyte colony-stimu-
lating factor when <10% of the primary amino groups
were attached to PEG [26]. In contrast, tumor necrosis fac-
tor-α as well as ADI retained approximately half of its bio-
logical activity when ~40–50% of its primary amines were
conjugated with PEG molecules [21,27]. We set out to
determine the effects of pegylation on the activity of argi-
nase – a urea cycle enzyme that can potentially be used in
anti-cancer treatment [2,4,28] – in an attempt to improve
its therapeutic properties.
A wide array of pegylation reagents are available. The NHS
esters of PEG carboxylic acids are the most popular deriv-
atives for coupling PEG to proteins. Reaction between
lysine and terminal amines and the active esters produces
a stable amide linkage. PEG succinimidyl succinate
(mPEG-SS) is one of the oldest and most used PEG deriv-
atives, but it possesses an ester linkage in its backbone and
thus has the property of undergoing hydrolysis in vivo. For
example, the ADI-PEGs studied by Holtsberg et al. [21]
were synthesized from succinimidyl succinate PEGs, with
PEG molecular weights of 5000 Da (ADI-SS PEG5000 mw)
and 20,000 Da (ADI-SS PEG20,000 mw). These ADI-PEGs
retained ~50% of enzyme activity when PEG was cova-
lently attached to ~40% of the primary amines irrespec-
tive of the PEG molecular weight.
The amine pegylating reagent mPEG-SPA does not have
an ester linkage in the backbone, they therefore generate
stable linkages, and they have nearly ideal reactivity for
protein modification. Moreover, mPEG-SPA 5,000 has
been used in several human applications. For example, it
has been used for attachment to a protein antagonist,
which has successfully completed clinical trials and an
NDA has been filed [23]. Therefore, the mPEG-SPA 5,000
process is validated and suitable for commercial use. In
the present study, the isolated and purified rhArg1 was
covalently attached via a succinamide propionic acid
(SPA) linker to polyethylene glycol (PEG) of MW 5,000.
Unlike many other pegylated enzymes, this pegylated
rhArg1 (rhArg1-peg5,000 mw) was fully active (Table 1). The
Km value for arginine as the substrate of the pegylated
rhArg1 was also much smaller (Km = 2.9 mM) than that of
the previously reported pegylated bovine liver arginase
(Km = 12 mM) (Savoca et al., 1979). Subsequently, the
pegylated rhArg1 was found to be stable enough in vivo to
maintain sufficient enzyme catalytic activity at physio-
logic pH [4].
Reaction conditions for coupling PEG to a protein vary
depending on the protein, the desired degree of pegyla-
tion and the PEG derivative utilized. Factors involved in
choice of derivative are: desired point of attachment
(lysine vs cysteine); hydrolytic stability and reactivity of
the derivative; stability of the linkage; and suitability for
CD spectroscopic analysisFigur  4
CD spectroscopic analysis. CD spectra (195–240 nm) of 
rhArg11 and rhArg11-peg5,000 mw under at 0.3 mg/ml in 10 
mM potassium phosphate buffer, pH 7.0, analysed in a Jasco J-
810 spectropolarimeter.Page 7 of 13
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various linkers (Fig. 1), and measurement of the relative
activities of the various types of pegylated rhArg1 (Table
1), showed that in most cases, pegylation had minimal
effects on the activity of rhArg1. Only the conjugation
with mPEG-CN produced a significant negative effect on
the enzyme's specific activity, which exhibited a drop of
~70% relative to the native rhArg1, whereas all the other
modifications only decreased the activities by ~10–15%.
The rhArg1 conjugated with mPEG-SPA (MW = 5000),
designated rhArg1-peg5,000 mw, retained >90% of the
native enzymatic activity, and was thus selected for further
studies. The observed 10% drop in activity of the rhArg1-
peg5,000 mw is favorable when compared to numerous
other proteins, such as ADI, granulocyte colony-stimulat-
ing factor (GCSF) and TNF-α, where pegylation normally
results in a 30–70% activity loss [21,26,27]. In the case of
mPEG-CN, not only was it once the most widely used rea-
gent for protein pegylation, it was also successfully used in
the pegylation of bovine liver arginase in 1979 [25].
Despite this, our mPEG-CN pegylated rhArg1 had the
lowest specific activity, retaining only ~30% of its native
activity (Table 1). This decrease in specific activity after
pegylation may be due to steric clash between the PEG
molecules and rhArg1's substrate which obstructs sub-
strate binding.
mPEG-NHS and mPEG-ALD were both also unsuitable
for the pegylation of rhArg1 as they did not sufficiently
react with the native enzyme, as shown by a large amount
of unpegylated rhArg1 in SDS-PAGE analysis (data not
shown). A possible explanation for this low yield is that
the mild pegylation conditions (in PBS buffer, pH 7.4,
25°C) were not suitable for the coupling of mPEG-NHS
and mPEG-ALD to arginase. Since the pegylated rhArg1 is
going to be targeted for therapeutic use, severe pegylation
conditions should be avoided as much as possible.
mPEG-MAL was also found to be an improper candidate
due to the relatively small size (low MW) of the pegylated
enzyme, which is a disadvantage as it is unlikely to be suf-
ficiently protected from degradation and would still have
a high rate of renal clearance [26]. In fact, there is a corre-
lation between the molecular size of the pegylated protein
and its circulatory half-life: the radii of pegylated protein
molecules are inversely related to the rate of renal clear-
ance [18]. As a consequence the half-life of the pegylated
protein would not be significantly prolonged. Therefore,
out of the 5 PEG molecules tested, our results showed
mPEG-SPA to be by far the most promising candidate for
further studies concerning the production of a therapeu-
tic-grade pegylated rhArg1. Based on our results, the opti-
mum rhArg1:PEG ratio and reaction duration were 1:50
and 3 h, respectively.
Gel electrophoresis (SDS-PAGE) does not provide quanti-
tative information because PEG "acts" much larger than
the proteins used for calibration (Fig. 2). However, this
sizing technique is extremely useful for qualitative analy-
sis of PEG proteins because it demonstrates the occurrence
of pegylation and it is very effective in monitoring repro-
ducibility of preparations. Determination of overall heter-
ogeneity in a PEG-protein (i.e., number of PEG-protein
forms present) remains difficult and is certainly not a rou-
tine matter. One of the most significant recent advances in
PEG and PEG-protein analysis has been the availability of
MALDI-TOF-MS. This technology provides the mass of the
unfragmented, singly-charged molecular ion of macro-
molecules up to about 100,000 Da, and thus greatly
assists determination of polydispersity and identity of
PEG derivatives. Similarly, the mass of the molecular ions
of PEG conjugates, such as PEG-proteins, can also be
determined, and the composition of pegylation reaction
products containing different numbers of PEGs ("one-
mer", "two-mer", etc.) can be established. As shown in
Fig. 3, rhArg1-peg5,000 mw has 1–6 molecules of PEG
attached to the amines of Lys residues of the arginase, and
under the reaction conditions we employed, the major
isotypes include the "two-mer", "three-mer" and "four-
mer".
The Km value of rhArg1 for arginine was 1.9 ± 0.7 mM.
However, the Km of the pegylated enzyme increased by ~1
mM, giving it a significantly higher Km when compared to
ADI, which has a Km of ~0.1–0.2 mM [28]. Although the
Km value of the pegylated rhArg1 seems to be rather high
to deplete efficiently plasma arginine (normal range
~100–150 μM) [28], it might be considered that this
enzyme would be incapable of depleting systemic
arginine levels unless it was present for a considerable
period of time at high dose levels, in particular when com-
pared with the biochemical attributes of ADI. Impor-
tantly, pegylation of rhArg1 with mPEG-SPA lengthened
the depletion period of serum arginine to one that is ther-
apeutically acceptable, and sufficiently long to compen-
Table 2: Secondary structure compositions of native and pegylated rhArg1 estimated by using CD analysis software.
Native rhArg1 rhArg1-peg5,000 mw Native rat liver arginase
α-Helix 25% 24% 22%
β-Sheet 27% 28% 28%
Turns 13% 17% 17%
Random structure 36% 32% 33%Page 8 of 13
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Pharmacodynamics of (A) native rhArg1 and (B) pegylated rhArg1 on plasma arginine in ratsFigure 5
Pharmacodynamics of (A) native rhArg1 and (B) pegylated rhArg1 on plasma arginine in rats. Sprague-Dawley 
rats were each injected i.p. with native or pegylated rhArg11. Plasma was collected at the indicated times, and arginine in each 
sample was determined by amino acid analysis. The data given as the means and 1 SD of 8 animals.
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doses would no longer have to be given to patients in
order to achieve and maintain arginine depletion. It is
also noteworthy that the Vmax of arginase compensates in
very good measure for its lower affinity, largely canceling
out the much lower Km for ADI.
The in vivo studies with rats confirmed the efficiency of
rhArg1-peg5,000 mw by showing that a single dose of 1,500
U was capable of depleting serum arginine levels for up to
6 days after the pegylated enzyme was administered (Fig.
5B). Intake of rhArg1-peg5,000 mw up to 4 weeks did not
produce any apparent ill effects in these animals, which
continued to gain weight with no behavioral changes.
Their blood, liver and renal chemistries, platelet counts
and clotting studies were normal throughout the study
(Table 3). This is consistent with the reported findings in
the pegylated ADI study, which is now in phase III clinical
development in Italy and MD Anderson Cancer Center in
Texas [22,29]. Our data are also consistent with the fact
that the mPEG-SPA advanced pegylation reagent is a clin-
ically proven stable attachment chemistry, which enables
improved therapeutic safety and efficacy and decreased
dosing frequency [23].
In conclusion, the pegylation of rhArg1 with mPEG-SPA
(MW 5,000) significantly prolonged the duration of
arginine depletion while retaining >90% of its activity,
and this has been shown to be sufficient to offset the low
activity of rhArg1 under physiological conditions, allow-
ing sustained arginine depletion to be achieved in vivo. We
also believed that the enzyme's half-life has been pro-
longed after pegylation, but it will need further elucida-
tion. Notably, PEG conjugation of rhArg1 still maintains
its tumor-specific efficacy (Table 4). Furthermore, we have
already shown that the growth of the ADI-resistant Hep3B
tumor cells in mice was inhibited by treatment with
Table 3: Hematological values, clinical biochemical findings, and organ weights in SD rats after weekly injection of rhArg1-peg5,000 mw 
for 4 weeks.
Parameters Control 15,000 U/kg 50,000 U/kg
Hematological values
RBC (× 1012/l) 8.25 ± 0.87 8.91 ± 0.90 8.20 ± 0.89
WBC (× 109/l) 5.27 ± 1.14 5.68 ± 1.08 4.02 ± 0.71*
Hb (g/l) 136.33 ± 17.25 134.50 ± 6.83 122.33 ± 6.80
MCH (pg) 16.50 ± 1.05 15.23 ± 1.67 15.00 ± 1.12*
MCHC (g/l) 342.00 ± 13.31 287.17 ± 35.82** 305.17 ± 19.26**
PLT (× 109/l) 742.50 ± 156.23 663.00 ± 121.51 545.83 ± 113.26*
HCT (%) 0.399 ± 0.05 0.474 ± 0.06* 0.403 ± 0.039
MCV (fl) 48.33 ± 2.25 53.18 ± 4.03* 49.17 ± 0.96
Clinical biochemical findings
ALT (nmol/l) 818.50 ± 69.16 796.83 ± 110.52 733.48 ± 118.66
CK (μmol/l) 112.60 ± 37.41 88.30 ± 27.17 88.14 ± 24.33
CH (mmol/l) 3.219 ± 0.51 2.500 ± 0.6** 2.879 ± 0.639
AST (nmol/l) 2883.90 ± 602.99 2622.20 ± 420.55 2300.46 ± 512.72
ALB (g/l) 42.60 ± 8.38 40.10 ± 18.83 35.86 ± 5.46
TP (g/l) 86.70 ± 12.49 76.20 ± 10.25 84.86 ± 15.08
BUN (mmol/l) 7.919 ± 3.267 9.305 ± 1.200 9.801 ± 0.815
TG (mmol/l) 3.129 ± 1.087 2.672 ± 1.175 2.832 ± 0.112
Organ weights (g)
Brain 0.380 ± 0.063 0.345 ± 0.050 0.324 ± 0.031*
Gland 0.071 ± 0.026 0.080 ± 0.037 0.074 ± 0.023
Heart 0.184 ± 0.021 0.180 ± 0.031 0.195 ± 0.020
Lung 0.237 ± 0.040 0.216 ± 0.051 0.233 ± 0.038
Notes: All values are expressed as mean ± standard deviation. RBC, red blood cell count; WBC, white blood cell count; Hb, hemoglobin; MCH, 
mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PLT, platelet count; HCT, hematocrit; MCV, mean 
corpuscular volume; ALT, alanine aminotransferase; CK, creatine kinase; CH, cholesterol; AST, aspartate aminotransferase; ALB, albumin; TP, total 
plasma protein; BUN, urea nitrogen in blood; and TG, triglycerides. Significant differences as compared with control by Duncan's t-test after 
ANOVA test (*p < 0.05; **p < 0.01).
Table 4: IC50 values of rhArg1 versus rhArg1-peg5,000 mw for 
human hepatocellular carcinomas in vitro. 
rhArg1 (U/ml) rhArg1-peg5,000 mw (U/ml)
HepG2 0.18 ± 0.06 0.22 ± 0.03
Hep3B 0.07 ± 0.03 0.10 ± 0.04
HepG2 and Hep3B were incubated in arginine-containing DMEM 
medium supplemented with 10% FBS with rhArg or rhArg1-peg5,000 
mw (0–100 U/ml) for 72 h at 37°C/5% CO2. IC50 values were 
calculated as the concentration of native rhArg1 or pegylated rhArg1 
which inhibited 50% cell growth. The experiments were repeated 
three times.Page 10 of 13
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alone and is synergistic in combination with 5-fluorour-
acil [4]. By broadening our knowledge of the biological
and pharmacological characteristics of both the rhArg1
and pegylated rhArg1, the present studies will make it pos-
sible to facilitate the development of arginase as pharma-
cological agents in the treatment of human cancer by
arginine deprivation. Treatment of human cancer (HCC)
patients with the chosen pegylated arginase has been
given on compassionate grounds, with consent. We are
therefore assured that the drug is safe to use in cancer clin-
ics. We believe that arginase (generally arginine deple-
tion) is going to be a significant force in cancer therapy
whether applied alone or in combination with other
drugs.
Methods
Pegylation of recombinant human arginase (rhArg1)
rhArg1 was obtained by producing the 6×His-tagged
human arginase I (liver arginase) enzyme in Bacillus subti-
lis [11]. The protein was pegylated in separate reactions
with the 5-methoxypolyethylene glycol (mPEG) of MW
5,000 (Fig. 1). mPEG-ALD, mPEG-MAL, mPEG-NHS, and
mPEG-SPA were purchased from Nektar Therapeutics
(Huntsville, AL, USA), and mPEG-CN from Sigma (St.
Louis, MO, USA). mPEG-ALD is readily oxidized by
atmospheric oxygen to produce the corresponding car-
boxylic acid, making storage under nitrogen essential for
this reagent, and thus points immediately to its. Deriva-
tives such as the succinimidyl active esters (mPEG-SPA
and mPEG-NHS) are reactive with moisture, and therefore
are stored in an argon atmosphere at -20°C.
Each type of PEG was conjugated with rhArg1 in PBS
buffer (pH 7.4) at a protein:PEG molar ratio of 1:20 or
1:50. Samples were stirred at 25°C for 3 h to allow suffi-
cient PEG molecules to react with rhArg1. The extent of
rhArg1 pegylation was analyzed by carrying out SDS-
PAGE, and protein concentration was determined by the
Bradford assay (Bio-Rad, Philadelphia, PA, USA). The
resulting products were exhaustively dialyzed against PBS
buffer (pH 7.4) using an FX 50 s High-Flux Dialyzer (Fre-
senius Polysulfone, Germany) in order to remove
unbound PEG molecules, which were stored at 4°C.
Enzyme activity and kinetic analysis of native and 
pegylated rhArg1
A coupled spectrophotometric assay, following the
decrease in absorbance at 340 nm (A340), was used to
determine arginase activity [12]. The specific activity of
the purified native rhArg1 was ~400 U/mg protein, 1 U of
arginase being defined as the amount of enzyme that can
produce 1 μmol urea/min at 30°C, pH 8.5.
To obtain kinetic data, including Km values, of the native
and pegylated rhArg1, the concentration of arginine was
varied from 0 to 50 mM and the corresponding changes in
A340 values were measured. The initial velocity data were
fitted with non-linear regression plots using Stanislawski's
program (Trinity Software, Plymouth, USA) to calculate
Km values.
Determination of the degree of pegylation by MALDI-
TOF-MS
PEG attached to one or more of several potential sites –
lysine and N-terminal amino groups – on the enzyme,
each attachment location defining a different isotype. The
distribution of PEG isotypes has interesting implications
in drug development process, which is because the prod-
uct must be defined by the distribution specification of
conjugation sites, i.e. the activity of the product is a func-
tion of the defined mixture.
The number of mPEG-SPA molecules attached to the pri-
mary amines of rhArg1 was determined by MALDI-TOF-
MS. Mass spectra were acquired using a Waters® Micromass®
MALDI micro MX™ Mass Spectrometer. Ions were gener-
ated by a nitrogen laser operating at a wavelength of 337
nm. Data were acquired in the positive linear mode of oper-
ation. The accelerating voltage in the ion source was 18 kV
and the extraction delay 500 ns. The matrix, 10 mg/ml
spinapinic acid, solution was freshly prepared in 50% of
0.1% aqueous trifluoroacetic acid and 50% acetonitrile.
Equal volume of matrix solution was mixed with the pro-
tein sample and 1.5 μl of the solution spotted on a stainless
steel sample plate. The mixture was allowed to air dry
before being introduced into the mass spectrometer.
Protein secondary structure analysis
Circular dichroism (CD) was used to identify any signifi-
cant changes in the secondary structure of rhArg1 after
pegylation. By measuring the CD spectra between 190 and
250 nm, the relative abundance of the various secondary
structural types were resolved [30,31], making it possible
to detect significant structural changes in the pegylated
enzyme. Native or pegylated rhArg1 (0.3 mg/ml) in 10
mM potassium phosphate (pH 7.0) was measured, using
a Jasco J-810 spectropolarimeter (Great Dunmow, UK) at
25°C using cuvettes of 1 mm path length. Each CD spec-
trum was the average of 2 scans and the CD signals were
expressed as mdeg.
Pharmacodynamic studies
Sprague-Dawley (SD) rats from the Chinese University of
Hong Kong (Shatin, Hong Kong) were used in the phar-
macodynamic studies. Normal SD rats (4 females and 4
males) of 3 months of age (average weight ~250 g) were
randomly assigned into 3 groups. Native rhArg1 (2,500
and 7,500 U per rat) or rhArg1-peg5,000 mw (1,500 U per
rat) were given i.p. on day 0. Blood samples were drawn
from their tail veins on day 0 before injection, and on days
1 to 6, and thereafter every 2 days. Blood was collected inPage 11 of 13
(page number not for citation purposes)
Cancer Cell International 2009, 9:9 http://www.cancerci.com/content/9/1/9EDTA and mixed with 50% trichloroacetic acid for precip-
itation of protein by incubating on ice for 30 min. The
samples were centrifuged at 13,000 × g for 15 min, and
arginine level in the clear supernatant fraction was ana-
lyzed by high-speed amino acid analyzer (model L-8800,
Hitachi). The plasma arginine levels at the indicated time
points were determined using the amino acid analyzer as
described by Cheng et al. [3].
Assessment of hematological and biochemical changes 
during arginine depletion in rats
Three groups of normal SD rats (40 per group) were given
saline, 15,000 U/kg, and 50,000 U/kg of rhArg1-peg5,000
mw once per week. The rats in each group was killed after 4
weeks and venous blood samples were taken to measure
hematological parameters such as hemoglobin, WBC,
platelet count, clotting studies (prothrombin time and
activated partial thromboplastin time), and full renal and
liver chemistries.
Inhibition of in vitro cancer cell proliferation
Liver cancer cell lines, HepG2 (HBV-negative hepatoblas-
toma, HB-8065) and Hep3B (HBsAg-positive HCC, HB-
8064), from American Type Culture Collection (Manas-
sas, USA), were grown in DMEM complete medium (Life
Technologies, Paisley, England) at 37°C in a humidified
atmosphere of 5% CO2 in air. Cells were seeded at ~2.5 ×
103 cells per well in 96-well plates and allowed to settle
overnight. The stated concentrations of rhArg1 and
rhArg1-peg5,000 mw were diluted into the growth medium
and the plates were incubated for 3 days. Quantitative cell
proliferation assays were performed using the MTS rea-
gent [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium] according to
the instructions provided by the manufacturer (Promega,
Madison, USA).
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